New drug combo aims to cure breast cancer that has spread to just a few places
NCT ID NCT05982678
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called trastuzumab-deruxtecan (T-DXd) in people with HER2-positive breast cancer that has spread to 1-3 distant spots (oligo-metastatic). The goal is to shrink or eliminate all cancer with a year of treatment, including local therapies like surgery or radiation, and potentially achieve a cure. About 72 participants will receive T-DXd every three weeks for 16 cycles.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Antoni van Leeuwenhoek
RECRUITINGAmsterdam, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?